Finally, exploiting endogenous protective mechanisms and pathways (e.g., the AnxA1/FPR2/ALX pathway) in neutrophils and platelets, thereby enabling the resolution of thromboinflammation, is going to be impactful in developing novel and potent therapies against stroke and will help drive effective pre-clinical and clinical therapeutic studies. Here, ANXA1 is linked to stroke disorder.